For decades, pancreatic cancer has occupied a grim place in medicine. It is one of the deadliest forms of cancer, notoriously difficult to detect early and stubbornly resistant to many treatments that have transformed outcomes in other diseases.
Now, researchers believe they may have reached a milestone that extends far beyond pancreatic cancer itself.
A new experimental drug called daraxonrasib has nearly doubled survival in patients with advanced pancreatic cancer, according to results from a major Phase 3 clinical trial involving 500 patients. The findings were so significant that oncologists attending the American Society of Clinical Oncology’s annual meeting in Chicago reportedly responded with a standing ovation.
The excitement is not simply about one drug or one disease. Scientists say the success represents something much larger. It demonstrates that some of cancer’s most elusive molecular targets, long considered impossible to treat, may finally be within reach.
For years, researchers referred to these targets as “undruggable.” The term reflected decades of failed attempts to develop medicines capable of shutting down the proteins responsible for driving some of the world’s deadliest cancers.
Today, that label is beginning to disappear.
A Disease That Has Defied Progress
Pancreatic cancer remains one of the most feared diagnoses in oncology.
Unlike many other cancers, it rarely causes obvious symptoms during its earliest stages. By the time patients experience warning signs such as abdominal pain, unexplained weight loss, digestive problems, jaundice, or persistent back pain, the disease has often spread beyond the pancreas.
This late detection contributes to exceptionally poor outcomes.
Historically, patients with metastatic pancreatic cancer have faced limited treatment options. Chemotherapy has remained the backbone of care for years, but survival improvements have been measured in months rather than years.
Researchers have made progress in understanding the disease’s biology, yet translating those discoveries into effective treatments has proven remarkably difficult.
One reason stands above all others.
More than 90 percent of pancreatic tumors are driven by mutations in a gene known as KRAS.
Scientists identified KRAS as a major cancer driver decades ago. Yet despite knowing its central role, they struggled to develop drugs capable of shutting it down.
The result was a frustrating paradox. Researchers understood the engine powering pancreatic cancer but could not find a way to switch it off.
The Protein Scientists Could Not Reach
To understand why the new findings are generating so much excitement, it helps to understand what made KRAS such a difficult target.
Proteins function as the machinery of life. Many modern cancer drugs work by attaching themselves to specific proteins and blocking harmful activity.
Most successful drug targets contain small pockets or grooves where medicines can bind.
KRAS offered almost none.
Researchers frequently describe the protein as unusually smooth. Without obvious binding sites, conventional drug design approaches repeatedly failed. Scientists could see the target clearly, but they could not find a way to hit it.
Over time, KRAS earned a reputation as one of the most famous “undruggable” proteins in medicine.
That reputation persisted for decades.
The challenge was especially frustrating because KRAS mutations are not limited to pancreatic cancer. They are also involved in many lung cancers, colorectal cancers, and several other tumor types.
A successful strategy against KRAS could potentially affect millions of patients worldwide.
Yet year after year, the breakthroughs never arrived.
The Drug That Changed Expectations
Daraxonrasib takes a very different approach from previous efforts.
Instead of attempting to directly bind to KRAS in the traditional way, the drug works through a mechanism that allows it to interfere with active RAS proteins and disrupt the signals that tell cancer cells to continue growing.
Importantly, the drug does not focus on a single mutation.
Earlier KRAS-targeting therapies were designed to work against specific genetic alterations. While valuable, those treatments only benefited relatively small groups of patients.
Daraxonrasib targets all three members of the RAS protein family, giving it the potential to affect a broader range of cancers driven by RAS activity.
Researchers describe it as a RAS(ON) inhibitor because it targets the active form of the protein.
The distinction may sound technical, but it represents years of scientific innovation aimed at overcoming one of oncology’s biggest obstacles.
The effort appears to have paid off.
The Trial Results That Stunned Oncologists
The Phase 3 study enrolled approximately 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.
Participants were randomly assigned to receive either daraxonrasib or chemotherapy selected by their physicians.
The results exceeded expectations.
Patients treated with daraxonrasib achieved a median overall survival of 13.2 months. Those receiving chemotherapy lived a median of 6.7 months.
For a disease where progress is often measured in incremental gains, nearly doubling survival is extraordinary.
The findings extended beyond overall survival.
Patients receiving the drug also experienced significantly longer progression-free survival. In simple terms, their cancer remained under control for a longer period before beginning to worsen.
Researchers reported progression-free survival of approximately 7.2 months in the daraxonrasib group compared with 3.6 months among patients receiving chemotherapy.
The magnitude of the improvement quickly drew attention throughout the oncology community.
Many experts described the data as practice-changing.
Others called it the most important pancreatic cancer advance in decades.
The reaction at the ASCO conference reflected that sentiment.
According to reports from the meeting, the presentation concluded with a prolonged standing ovation, an uncommon occurrence in scientific medicine.
Ecaterina Dumbrava, an oncologist at MD Anderson Cancer Center, described the moment as emotional after years of limited progress against pancreatic cancer.
Better Outcomes Without Greater Toxicity
Cancer treatments are often judged by more than survival numbers alone.
Quality of life matters enormously, particularly for patients facing advanced disease.
One of the most encouraging aspects of the trial involved tolerability.
Like nearly all cancer drugs, daraxonrasib caused side effects.
The most common included rash, diarrhea, nausea, vomiting, fatigue, and inflammation inside the mouth.
The skin rash was especially frequent, affecting a large percentage of patients.
Despite these issues, researchers found that severe treatment-related side effects occurred less often than with chemotherapy.
Patients receiving daraxonrasib were also far less likely to discontinue treatment because of adverse effects.
Only a small percentage stopped treatment because of drug-related complications, compared with a much higher percentage among patients receiving chemotherapy.
Researchers additionally reported improvements in patient-reported quality-of-life measures.
For many individuals with metastatic pancreatic cancer, maintaining daily function and reducing symptoms can be nearly as important as extending survival.
The combination of improved outcomes and manageable side effects has strengthened optimism surrounding the therapy.
Why Researchers Believe This Is Bigger Than Pancreatic Cancer
The story does not end with one successful trial.
Many scientists see daraxonrasib as proof that supposedly impossible cancer targets can be conquered.
That shift in thinking may influence cancer research for years.
The success has renewed interest in several proteins that researchers once viewed as nearly untouchable.
These proteins have long occupied the same category as KRAS: biologically important, clearly linked to cancer, yet frustratingly resistant to traditional drug development approaches.
Now there is growing belief that those assumptions may need revising.
Kevan Shokat, a chemical biologist at the University of California, San Francisco, has suggested that the first successful drugs often serve as proof that a problem can be solved, even if later versions become more effective.
The lesson extends beyond a single molecule.
It suggests that persistence, new technologies, and creative chemistry can eventually overcome barriers that once appeared permanent.
The Race to Target MYC
Among the most closely watched targets is a protein known as MYC.
If KRAS has dominated discussions around pancreatic cancer, MYC occupies a similarly important role across many other cancers.
Researchers estimate that roughly 70 percent of cancers involve excessive MYC activity.
The protein influences cell growth, metabolism, and gene expression. When it becomes overactive, cancer cells can gain a significant advantage.
Yet MYC presents many of the same challenges that frustrated KRAS researchers for decades.
Its surface is difficult for drugs to bind.
The genetic changes that activate MYC are often complex and vary from tumor to tumor.
As a result, scientists have spent years searching for effective ways to inhibit its activity.
Several experimental programs are now advancing through development.
One candidate known as OMO-103 has already shown encouraging signals in early human studies.
Elsewhere, researchers are using artificial intelligence to identify compounds capable of disrupting critical MYC functions.
The growing momentum behind these efforts stems partly from the success of KRAS-directed therapies.
Investors, pharmaceutical companies, and academic researchers increasingly believe that difficult targets deserve another look.
The Revival of p53
Another protein generating excitement is p53.
Often called the “guardian of the genome,” p53 plays a central role in protecting cells from DNA damage.
When functioning properly, it helps prevent damaged cells from becoming cancerous.
Unfortunately, mutations affecting p53 are among the most common genetic alterations found in human cancers.
For years, researchers faced a different challenge with p53 than with KRAS.
Instead of trying to shut down an overactive protein, they needed to restore the function of a damaged one.
That task proved extraordinarily difficult.
Recent results, however, suggest meaningful progress.
A drug known as rezatapopt has demonstrated encouraging activity against tumors carrying a specific p53 mutation called Y220C.
The treatment works by stabilizing the altered protein and helping restore its normal behavior.
Although current studies remain relatively small, researchers are hopeful that success against one mutation could lead to therapies targeting many others.
Some experts have already begun referring to p53 as the next major frontier after KRAS.
Another Long Pursuit: Beta-Catenin
The protein beta-catenin offers another example of a target that once seemed almost impossible to drug safely.
Researchers first became interested in beta-catenin because of its role in colorectal cancer and several other tumor types.
The challenge was that beta-catenin also performs essential functions throughout the body.
Blocking it completely risked causing serious side effects.
Scientists therefore needed a more precise approach.
An experimental drug called zolucatetide appears to offer one possible solution.
Rather than shutting down the protein entirely, the therapy selectively interferes with specific interactions that contribute to cancer growth.
Early clinical trial results have generated optimism.
According to researchers involved in its development, some patients have remained on treatment for years while continuing to benefit.
Although much work remains, the results suggest that even highly complex biological pathways may be vulnerable to carefully designed therapies.
A New Era for Precision Cancer Medicine
The broader significance of daraxonrasib lies in what it represents for cancer treatment as a whole.
For decades, many therapies relied on broadly attacking rapidly dividing cells.
While these approaches saved countless lives, they often caused substantial damage to healthy tissues.
Targeted therapies pursue a different goal.
Rather than attacking all rapidly dividing cells, they seek to identify the specific molecular abnormalities driving a patient’s cancer.
The success of daraxonrasib reflects the growing sophistication of that strategy.
Researchers are no longer limited to the easiest targets.
Advances in structural biology, computational modeling, artificial intelligence, medicinal chemistry, and protein engineering have dramatically expanded the range of possibilities.
Problems that appeared unsolvable 20 years ago are increasingly becoming tractable.
This does not mean every difficult cancer target will yield quickly.
Many obstacles remain.
Tumors evolve. Resistance develops. Biological systems are complex.
Yet the trajectory has changed.
Scientists are moving from asking whether these targets can be drugged to determining the best way to do it.
What Comes Next
The immediate focus will be regulatory review.
With Phase 3 data now published and presented to the oncology community, Revolution Medicines is expected to seek approval from health authorities in the United States and other countries.
If approved, daraxonrasib could become a new standard treatment for previously treated metastatic pancreatic cancer.
Researchers are also exploring combination strategies designed to extend benefits even further.
Many experts believe pairing daraxonrasib with other targeted therapies could help prevent resistance and improve long-term outcomes.
Additional studies will examine whether the drug can benefit patients earlier in the course of disease and whether similar approaches can be applied across other cancers driven by RAS signaling.
For patients facing pancreatic cancer today, those future developments cannot arrive soon enough.
For the scientific community, however, the message from this trial is already clear.
One of cancer research’s most famous dead ends has become a roadmap. A protein once viewed as impossible to target has yielded a treatment capable of changing survival outcomes. The achievement may ultimately be remembered not only for what it accomplished in pancreatic cancer, but for the confidence it has given researchers pursuing every other “undruggable” target still waiting on the horizon.
